We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (9 April 2024) approved the medicine fosdenopterin (Nulibry) to treat the genetic disease Molybdenum Cofactor Deficiency (MoCD) Type A
Check the tariff classification for the unassembled parts to be implanted into the human body for different spinal treatments.
How we evaluated pre-exposure prophylactic (preventative) treatments for COVID-19.
The MHRA will introduce a patient alert card to increase awareness among men taking finasteride about potential psychiatric and sexual side effects
Collection of documents relating to COVID-19 treatments.
Legal terms for veterinary medicines, marketing of non-medicinal products including medicinal words and phrases, how to complain.
How to notify the MHRA of your intention to carry out a clinical investigation for medical devices.
Get help to classify herbal medicines, vitamins, food preparations, supplements and tonics for import and export.
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (7 March 2024) approved the medicine ganaxolone (Ztalmy) as the first anti-seizure medication in the UK to treat cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD).
Further measures to be introduced to ensure patients who are prescribed montelukast for the treatment of asthma are informed of the risk of neuropsychiatric reactions
How to get a marketing authorisation for an Advanced Therapy Medicinal Product (ATMP) so it can be sold and/or supplied in Great Britain.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
The way you apply to licence biological products has changed
Volume 35 of the non-technical summaries granted under the Animals (Scientific Procedures) Act 1986 during 2013.
Following a review, the MHRA has updated previous guidance (DSI/2022/003) on the use of paclitaxel coated devices (PCD) in the treatment of peripheral arterial disease (PAD).
The Vaccine Development Evaluation Centre (VDEC) at Porton Down in Wiltshire facilitates the development and evaluation of new vaccines and therapeutics.
Outcome(s) by the Central Arbitration Committee on an application from the RMT.
How the MHRA makes decisions on when a product is a medical device (borderline products), and which risk class should apply to a medical device.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.